3种抗生素治疗急性呼吸道感染成本—效果分析

目的评价3种抗生素治疗急性呼吸道感染的经济学效果。方法将188例急性呼吸道感染患者随机分为A左氧氟沙星组（68例）、B环丙沙星组（56例）、C莫西沙星组（64例），用成本—效果分析法进行评价。结果A、B、C三组的治愈率分别为73.53％、85.71％和93.75％（P〈0.05）；成本分别为397.60元、1131．90元和2255.40元（P〈0.05）；成本—效果比分别为5．40、13．20和24.05。B、C组相对于A组的增量成本—效果比分别是60．28和91。87，3组均未发生与治疗药物相关的严重不良反应。结论A组方案（左氧氟沙星）最经济。

Objective To evaluated the economic effectiveness of 3 antibiotics for acute lower respiratory infection. Methods 188 cases of acute lower respiratory infection were randomly divided into the A levofloxacin （68 cases） group, B ciprofloxacin （56 cases） group and C moxifloxacin （64cases） group. The costeffectiveness analysis was adopted to evaluate the treatment effect. Results The cure rates of Group A, B and C were 73.53%, 85.71% and 93.75% （P〈0.05） respectively. The cost was 397.60 yuan, 1131.90 yuan and 2255.40 yuan （P〈0.05） respectively, and the cost- effectiveness ratios was 5.40, 13.20 and 24.05. The increment cost-effectiveness ratios of B, C group compared with A group was 60.28 and 91.87 respectively. No severe adverse reactions related to the treatment drugs were found in the 3 groups. Conclusion Group A （levofloxacin） is the most economic.